|
|
Upfront Briefing
Monday was a checkbook day: strategic buyers kept signing while everyone else waited on Big Tech earnings. BMS threw down for the biggest AI supercomputer in life sciences, Tempus reached for Personalis at $1.5B in stock, and Lilly's psychedelics bet kept drawing a crowd — selective capital allocation, not a spending spree.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,443.3 |
(0.2%) |
8.5% |
| Nasdaq 100 |
28,604.2 |
0.0% |
13.5% |
| Russell 2000 |
2,942.4 |
(0.7%) |
17.3% |
| Healthcare (XLV) |
159.2 |
(1.1%) |
2.4% |
| Biotech (XBI) |
150.9 |
(2.2%) |
24.2% |
| Nasdaq Biotech (NBI) |
6,447.5 |
(1.8%) |
13.0% |
| Clinical Trials (BBC) |
49.7 |
(2.4%) |
32.2% |
|
- A heavy M&A tape — Samsung–PolyPeptide and Tempus–Personalis — couldn't offset broad risk-off; XBI fell 2.2% and NBI 1.8% as investors booked profits after a 24% YTD XBI run.
- The broad tape slipped (S&P 500 (0.2%)) as crude climbed on the ninth straight day of U.S. strikes on Iran, driving a modest safe-haven bid ahead of Big Tech earnings.
- Market data: U.S. cash close Monday, 20 July 2026.
The Big 3
|
1
|
BMS bets big on AI, building its 'most powerful AI factory in life sciences' with Nvidia
|
- Bristol Myers Squibb expanded its Nvidia collaboration to deploy DGX SuperPOD infrastructure (Vera Rubin NVL72) for drug R&D — what it bills as the "most powerful, energy-efficient single-owned Nvidia infrastructure in life sciences," building on a three-year partnership. No financial terms were disclosed.
- Why it matters: The move plants BMS in an escalating big-pharma AI arms race — Lilly has committed $1B to an Nvidia co-innovation lab, and Roche and Qiagen have struck their own Nvidia deals. The pitch is "hybrid intelligence" to lift pipeline hit rates as BMS stares down LOE pressure on Revlimid and Eliquis. The catch: heavy compute capex with ROI still unproven — the Street has yet to reward AI infrastructure spend with actual pipeline output, so this reads as a capability bet, not a financeable catalyst.
- Source: Fierce Biotech
- More: BMS release
|
|
2
|
After Lilly, the psychedelics bid list gets short
|
- With Lilly's $2.8B AtaiBeckley buy closing Q3, the read-through is who's left: Compass Pathways (CMPS) and GH Research (GHRS) both rallied on the news, and Jefferies now calls big pharma's interest in the space "rising."
- Why it matters: Four buyers are now in: J&J via Spravato (~$2B in sales), AbbVie through Gilgamesh, Otsuka via Transcend, and now Lilly. That reprices the independents rather than any one of them — GHRS jumped roughly 15% on the Lilly print, CMPS around 7%, Definium about 6%, which is the market pricing takeout odds, not fundamentals. Compass is the name Wall Street floats next: a de-risked COMP360 psilocybin package with a rolling FDA submission underway and a decision possible late 2026, exactly the profile Lilly and AbbVie just paid up for. The FDA's July 14 psychedelic clinical guidance removes the overhang that kept acquirers out for a decade. The risk cuts the other way — a name trading on bid speculation gives most of it back if the next deal doesn't come, and in-clinic administration remains the real commercial bottleneck across all of these.
-
Source:
Fierce Biotech
|
| 3 | Tempus to buy Personalis for $1.5B |
-
Tempus is acquiring Personalis in an all-stock deal at $16.25/share (~$1.5B enterprise value, ~6% premium), folding the NeXT Personal MRD test into its precision-oncology platform.
-
Why it matters:
The buy pulls molecular residual disease in-house and sets a valuation marker for tissue-informed MRD, the fastest-growing slice of liquid biopsy. Tempus shares slid on the print as investors weighed all-stock dilution against a thin premium — a signal the Street wants MRD accretion proven, not promised.
-
Source:
BioPharma Dive
-
More:
Tempus;
Benzinga
|
Everything Else that broke
- Kolon TissueGene's cell-based gene therapy missed both co-primary endpoints in a phase 3 osteoarthritis trial; a second late-stage readout is due in October. — Fierce Biotech
- Novartis posted Q2 sales growth and reaffirmed full-year guidance. — PR
- Canada's top court upheld the bar on medical treatment patents in a Janssen paliperidone case. — PR
- House lawmakers backed a trade probe into China biotech and sequencing. — Fierce Biotech
- The FDA's CRL publication policy ran into legal uncertainty. — BioSpace
- Calidi set a 1-for-16 reverse split, with adjusted trading due July 31. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- ICYMI: Samsung Biologics agreed to acquire PolyPeptide for $1.8B all-cash (CHF 44.31/share, 40% premium). — Fierce Pharma
- Tempus agreed to acquire Personalis in an all-stock deal at ~$1.5B EV ($16.25/share). — BioPharma Dive
-
Cardinal Health added two home-care tuck-ins, including AdaptHealth's Diabetes Health business. — PR
-
Lupin spun out oncology programs LNP7457 and LNP8701 to Kaveri Therapeutics. — PR
- Bio-Techne drew activist pressure after Ananym Capital urged a strategic review that could include a sale. — Reuters
VC / Private Financings
- No notable venture rounds in the last 24 hours.
IPOs / Follow-Ons
- Latigo outlined IPO plans for its non-opioid sodium ion channel pain pipeline. — BioPharma Dive
- Scribe targeted a roughly $96.2M IPO at a $14 midpoint, with upside to about $110.2M if underwriters fully exercise the option. — Fierce Biotech
- REGENXBIO priced a $100.0M public offering of common stock and pre-funded warrants, with closing expected July 20. — PR
Academic Corner - Structural work mapped how oligoclonal T cells recognize a shared NRAS cancer neoantigen. — Cell
|
That's the tape. Deals up, indices down — someone's always buying the dip, even if it's a $1.8B one.
— BioBucks Team
|
|
|
